Department of Emergency, Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
J Thorac Oncol. 2012 Jan;7(1):76-84. doi: 10.1097/JTO.0b013e318232b98a.
Thyroid transcription factor-1 (TTF1) plays a role in lung adenocarcinoma development. We investigated the significance of TTF1 in primary lung adenocarcinomas, lymph node metastases, and malignant pleural effusions (MPEs).
We studied TTF1 in 175 primary lung adenocarcinomas, 52 lymph node metastases, and 46 MPE using microarray-based fluorescence in situ hybridization, immunohistochemistry, and messenger RNA (mRNA) in situ hybridization. Real-time reverse transcription polymerase chain reaction was used to investigate correlations between TTF1 amplification and mRNA expression. Correlations between clinicopathologic characteristics, TTF1 amplification, TTF1 expressions, overall survival, and prognosis were analyzed.
TTF1 was amplified in 7% of primary lung adenocarcinomas, 4% of lymph node metastases, and 4% of MPE. TTF1 amplification in lung adenocarcinomas was associated with pathologic subtypes (p = 0.029). Patients with positive TTF1 protein and mRNA expressions had improved overall survival if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). A multivariate model did not show patients with positive TTF1 expressions tended to have better prognoses if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). Survival time was longer for patients with TTF1 expressions in both primary lung tissues (p < 0.001) and MPE (p = 0.045). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma (p < 0.001). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma tissues (p < 0.001) while not in MPE (p = 0.058). TTF1 mRNA level was higher in cases with TTF1 amplification compared with those without TTF1 amplification.
Patients with lung adenocarcinoma without TTF1 amplification tend to have better prognoses than those with TTF1 amplification in cases with positive TTF1 expressions. Positive TTF1 expressions in lung adenocarcinoma tissues are favorable prognostic parameters in patients with lung adenocarcinoma.
甲状腺转录因子-1（TTF1）在肺腺癌的发展中发挥作用。我们研究了 TTF1 在原发性肺腺癌、淋巴结转移和恶性胸腔积液（MPE）中的意义。
我们使用基于微阵列的荧光原位杂交、免疫组织化学和信使 RNA（mRNA）原位杂交研究了 175 例原发性肺腺癌、52 例淋巴结转移和 46 例 MPE 中的 TTF1。实时逆转录聚合酶链反应用于研究 TTF1 扩增与 mRNA 表达之间的相关性。分析了 TTF1 扩增、TTF1 表达、总生存期和预后与临床病理特征之间的相关性。
在 7%的原发性肺腺癌、4%的淋巴结转移和 4%的 MPE 中扩增了 TTF1。肺腺癌中 TTF1 扩增与病理亚型有关（p = 0.029）。如果 TTF1 未扩增，TTF1 蛋白和 mRNA 表达阳性的患者总生存期优于 TTF1 扩增的患者（p = 0.068）。多变量模型显示，与 TTF1 扩增的患者相比，TTF1 表达阳性且 TTF1 未扩增的患者预后更好（p = 0.068）。在原发性肺组织（p < 0.001）和 MPE（p = 0.045）中均有 TTF1 表达的患者的生存时间更长。多变量模型证实 TTF1 表达在肺腺癌中的预后价值（p < 0.001）。多变量模型证实 TTF1 表达在肺腺癌组织中的预后价值（p < 0.001），而在 MPE 中无此价值（p = 0.058）。与 TTF1 未扩增的病例相比，TTF1 扩增的病例中 TTF1 mRNA 水平更高。
在 TTF1 表达阳性的情况下，与 TTF1 扩增的患者相比，TTF1 未扩增的肺腺癌患者的预后更好。肺腺癌组织中 TTF1 表达阳性是肺腺癌患者的有利预后参数。
